Literature DB >> 16946302

Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.

Norbert Schmitz1, Mary Eapen, Mary M Horowitz, Mei-Jie Zhang, John P Klein, J Douglas Rizzo, Fausto R Loberiza, Alois Gratwohl, Richard E Champlin.   

Abstract

We previously compared outcomes after allogeneic peripheral-blood stem cell (PBSC) and bone marrow (BM) transplantation in 706 patients with leukemia. We obtained long-term follow up on 413 of 491 patients who were alive at the time of the initial report: 141 PBSC and 272 BM recipients. Chronic graft-versus-host disease (GVHD) was more frequent after PBSC compared to BM transplantation (RR 1.65, P < .001) yet relapse rates were similar in both groups. Leukemia-free survival rates were higher after PBSC than BM transplantation for patients with advanced chronic myeloid leukemia (33% versus 25%) but lower for those in first chronic phase (41% versus 61%) due to higher rates of late transplant-related mortality. Leukemia-free survival was similar after PBSC and BM transplantation for acute leukemia. These data represent the early experience with PBSC grafts. Long-term outcomes in recipients of more recent transplants are required to better evaluate the role of PBSC grafts relative to BM transplantation.

Entities:  

Mesh:

Year:  2006        PMID: 16946302      PMCID: PMC1895450          DOI: 10.1182/blood-2006-05-024042

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.

Authors:  D Blaise; M Kuentz; C Fortanier; J H Bourhis; N Milpied; L Sutton; J P Jouet; M Attal; P Bordigoni; J Y Cahn; J M Boiron; M P Schuller; J P Moatti; M Michallet
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.

Authors:  Stephen Couban; David R Simpson; Michael J Barnett; Christopher Bredeson; Lothar Hubesch; Kang Howson-Jan; Tsiporah B Shore; Irwin R Walker; Peter Browett; Hans A Messner; Tony Panzarella; Jeffrey H Lipton
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

3.  Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia.

Authors:  O Ringdén; M Labopin; A Bacigalupo; W Arcese; U W Schaefer; R Willemze; H Koc; D Bunjes; E Gluckman; V Rocha; A Schattenberg; F Frassoni
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

4.  Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial.

Authors:  R Powles; J Mehta; S Kulkarni; J Treleaven; B Millar; J Marsden; V Shepherd; A Rowland; B Sirohi; D Tait; C Horton; S Long; S Singhal
Journal:  Lancet       Date:  2000-04-08       Impact factor: 79.321

5.  Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.

Authors:  Norbert Schmitz; Meral Beksac; Andrea Bacigalupo; Tapani Ruutu; Arnon Nagler; Eliane Gluckman; Nigel Russell; Jane Apperley; Jeff Szerm; Kenneth Bradstock; Agnes Buzyn; Brigitte Schlegelberger; James Matcham; Alois Gratwohl
Journal:  Haematologica       Date:  2005-05       Impact factor: 9.941

6.  Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.

Authors: 
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

7.  Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.

Authors:  C Cutler; S Giri; S Jeyapalan; D Paniagua; A Viswanathan; J H Antin
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

8.  Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  R E Champlin; N Schmitz; M M Horowitz; B Chapuis; R Chopra; J J Cornelissen; R P Gale; J M Goldman; F R Loberiza; B Hertenstein; J P Klein; E Montserrat; M J Zhang; O Ringdén; S C Tomany; P A Rowlings; M E Van Hoef; A Gratwohl
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

9.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.

Authors:  W I Bensinger; P J Martin; B Storer; R Clift; S J Forman; R Negrin; A Kashyap; M E Flowers; K Lilleby; T R Chauncey; R Storb; F R Appelbaum
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

10.  Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.

Authors:  Norbert Schmitz; Meral Beksac; Dirk Hasenclever; Andrea Bacigalupo; Tapani Ruutu; Arnon Nagler; Eliane Gluckman; Nigel Russell; Jane F Apperley; Norbert C Gorin; Jeff Szer; Ken Bradstock; Agnes Buzyn; Peter Clark; Keith Borkett; Alois Gratwohl
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

View more
  39 in total

1.  Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow.

Authors:  Marco Mielcarek; Barry Storer; Paul J Martin; Stephen J Forman; Robert S Negrin; Mary E Flowers; Yoshihiro Inamoto; Thomas R Chauncey; Rainer Storb; Frederick R Appelbaum; William I Bensinger
Journal:  Blood       Date:  2012-02-03       Impact factor: 22.113

Review 2.  Who is fit for allogeneic transplantation?

Authors:  H Joachim Deeg; Brenda M Sandmaier
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

Review 3.  Prevention of graft-vs.-host disease.

Authors:  Andrew R Rezvani; Rainer F Storb
Journal:  Expert Opin Pharmacother       Date:  2012-07-07       Impact factor: 3.889

4.  Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia.

Authors:  Roland Chu; Ruta Brazauskas; Fangyu Kan; Asad Bashey; Christopher Bredeson; Bruce Camitta; Kuang-Yueh Chiang; Haydar Frangoul; Robert Peter Gale; Adrian Gee; Biju George; Frederick D Goldman; Thomas G Gross; Vikas Gupta; Gregory A Hale; Luis Isola; Alvaro Urbano Ispizua; Hillard Lazarus; Judith Marsh; James Russell; Mitchell Sabloff; Edmund K Waller; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

Review 5.  Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.

Authors:  F Saraceni; N Shem-Tov; A Olivieri; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

6.  Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.

Authors:  Parameswaran Hari; Jeanette Carreras; Mei-Jie Zhang; Robert Peter Gale; Brian J Bolwell; Christopher N Bredeson; Linda J Burns; Mitchell S Cairo; César O Freytes; Steven C Goldstein; Gregory A Hale; David J Inwards; Charles F Lemaistre; Dipnarine Maharaj; David I Marks; Harry C Schouten; Shimon Slavin; Julie M Vose; Hillard M Lazarus; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2008-02       Impact factor: 5.742

7.  Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.

Authors:  Hubert Schrezenmeier; Jakob R Passweg; Judith C W Marsh; Andrea Bacigalupo; Christopher N Bredeson; Eduardo Bullorsky; Bruce M Camitta; Richard E Champlin; Robert Peter Gale; Monika Fuhrer; John P Klein; Anna Locasciulli; Rosi Oneto; Antonius V M B Schattenberg; Gerard Socie; Mary Eapen
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

8.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.

Authors:  Stephanie J Lee; Manisha Kukreja; Tao Wang; Sergio A Giralt; Jeffrey Szer; Mukta Arora; Ann E Woolfrey; Francisco Cervantes; Richard E Champlin; Robert Peter Gale; Joerg Halter; Armand Keating; David I Marks; Philip L McCarthy; Eduardo Olavarria; Edward A Stadtmauer; Manuel Abecasis; Vikas Gupta; H Jean Khoury; Biju George; Gregory A Hale; Jane L Liesveld; David A Rizzieri; Joseph H Antin; Brian J Bolwell; Matthew H Carabasi; Edward Copelan; Osman Ilhan; Mark R Litzow; Harold C Schouten; Axel R Zander; Mary M Horowitz; Richard T Maziarz
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

9.  Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Susan F Leitman; Paolo Anderlini; John P Klein; Mary M Horowitz; John P Miller; Roberta J King; Dennis L Confer
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

10.  Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

Authors:  Courtney D Fitzhugh; Matthew M Hsieh; Charles D Bolan; Carla Saenz; John F Tisdale
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.